Enovis (0I1B) Share Forecast & Price Target

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0I1B Analyst Ratings

Strong Buy

10 Buy

1 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Enovis

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0I1B Stock 12 Month Forecast

Average Price Target

$39.10

▲(34.09% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Enovis in the last 3 months. The average price target is $39.10 with a high forecast of $52.00 and a low forecast of $27.00. The average price target represents a 34.09% change from the last price of $29.16.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","36":"$36","53":"$53","27.5":"$27.5","44.5":"$44.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,27.5,36,44.5,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.46,24.732307692307693,27.004615384615384,29.276923076923076,31.549230769230768,33.82153846153846,36.09384615384616,38.36615384615385,40.63846153846154,42.91076923076923,45.183076923076925,47.45538461538462,49.72769230769231,{"y":52,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.46,23.740000000000002,25.02,26.3,27.580000000000002,28.86,30.14,31.42,32.7,33.980000000000004,35.260000000000005,36.54,37.82,{"y":39.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.46,22.80923076923077,23.158461538461538,23.50769230769231,23.856923076923078,24.206153846153846,24.555384615384614,24.904615384615386,25.253846153846155,25.603076923076923,25.95230769230769,26.301538461538463,26.65076923076923,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.77,"date":1756674000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.959,"date":1759266000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.018,"date":1761948000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.795,"date":1764540000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.51,"date":1767218400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.515,"date":1769896800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.06,"date":1772316000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.98,"date":1774990800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.63,"date":1777582800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.17,"date":1780261200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.35,"date":1782853200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.04,"date":1785531600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.46,"date":1788210000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$52.00

Average Price Target$39.10

Lowest Price Target$27.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Larry Biegelsen

Wells Fargo

$39→$33

Buy

13.17%

Upside

Assigned

09/02/26

Analysts Offer Insights on Healthcare Companies: Enovis (NYSE: ENOV), Adicet Bio (NASDAQ: ACET) and Definium Therapeutics (NASDAQ: DFTX)

David Turkaly

Citizens JMP

$55→$47

Buy

61.18%

Upside

Reiterated

09/02/26

Enovis price target lowered to $47 from $55 at CitizensEnovis price target lowered to $47 from $55 at Citizens

Michael Matson

Needham

$52

Buy

78.33%

Upside

Reiterated

09/01/26

Analyst Reiterates Buy on Enovis, Maintains $52 Price Target Following Strategic eCential Robotics Acquisition

Caitlin Cronin

Canaccord Genuity

$45

Buy

54.32%

Upside

Reiterated

09/01/26

Canaccord Genuity Remains a Buy on Enovis (ENOV)

Ryan Zimmerman

BTIG

$39→$36

Buy

23.46%

Upside

Reiterated

09/01/26

Enovis: Buy Rating Reaffirmed as Surgical Robotics Acquisition Closes Competitive Gap; Price Target Trimmed to $36 on Deal-Related Costs and Leverage

Vik Chopra

BMO Capital

$30→$27

Buy

-7.41%

Downside

Assigned

09/01/26

Enovis price target lowered to $27 from $30 at BMO CapitalEnovis price target lowered to $27 from $30 at BMO Capital

Steven Lichtman

William Blair

―

Buy

―

Reiterated

08/14/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Enovis (NYSE: ENOV) and Lantheus (NASDAQ: LNTH)

Robbie Marcus

J.P. Morgan

$28

Hold

-3.98%

Downside

Reiterated

08/10/26

J.P. Morgan Sticks to Its Hold Rating for Enovis (ENOV)

Vijay Kumar

Evercore ISI

$32

Buy

9.74%

Upside

Reiterated

08/07/26

Evercore ISI Sticks to Their Buy Rating for Enovis (ENOV)

Patrick Wood

UBS

$50→$51

Buy

74.90%

Upside

Initiated

07/28/26

Enovis assumed with a Buy at UBSEnovis assumed with a Buy at UBS

Rong Li

Jefferies

$40

Buy

37.17%

Upside

Reiterated

07/14/26

Enovis (ENOV) Receives a Buy from Jefferies

Jeff Johnson

Robert W. Baird

$45→$37

Buy

26.89%

Upside

Reiterated

05/08/26

Enovis price target lowered to $37 from $45 at BairdEnovis price target lowered to $37 from $45 at Baird

Keith Hinton

Freedom Capital Markets

$45

Buy

54.32%

Upside

Initiated

12/16/25

Enovis (ENOV) Initiated with a Buy at Freedom Capital Markets

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Larry Biegelsen

Wells Fargo

$39→$33

Buy

13.17%

Upside

Assigned

09/02/26

Analysts Offer Insights on Healthcare Companies: Enovis (NYSE: ENOV), Adicet Bio (NASDAQ: ACET) and Definium Therapeutics (NASDAQ: DFTX)

David Turkaly

Citizens JMP

$55→$47

Buy

61.18%

Upside

Reiterated

09/02/26

Enovis price target lowered to $47 from $55 at CitizensEnovis price target lowered to $47 from $55 at Citizens

Michael Matson

Needham

$52

Buy

78.33%

Upside

Reiterated

09/01/26

Analyst Reiterates Buy on Enovis, Maintains $52 Price Target Following Strategic eCential Robotics Acquisition

Caitlin Cronin

Canaccord Genuity

$45

Buy

54.32%

Upside

Reiterated

09/01/26

Canaccord Genuity Remains a Buy on Enovis (ENOV)

Ryan Zimmerman

BTIG

$39→$36

Buy

23.46%

Upside

Reiterated

09/01/26

Enovis: Buy Rating Reaffirmed as Surgical Robotics Acquisition Closes Competitive Gap; Price Target Trimmed to $36 on Deal-Related Costs and Leverage

Vik Chopra

BMO Capital

$30→$27

Buy

-7.41%

Downside

Assigned

09/01/26

Enovis price target lowered to $27 from $30 at BMO CapitalEnovis price target lowered to $27 from $30 at BMO Capital

Steven Lichtman

William Blair

―

Buy

―

Reiterated

08/14/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Enovis (NYSE: ENOV) and Lantheus (NASDAQ: LNTH)

Robbie Marcus

J.P. Morgan

$28

Hold

-3.98%

Downside

Reiterated

08/10/26

J.P. Morgan Sticks to Its Hold Rating for Enovis (ENOV)

Vijay Kumar

Evercore ISI

$32

Buy

9.74%

Upside

Reiterated

08/07/26

Evercore ISI Sticks to Their Buy Rating for Enovis (ENOV)

Patrick Wood

UBS

$50→$51

Buy

74.90%

Upside

Initiated

07/28/26

Enovis assumed with a Buy at UBSEnovis assumed with a Buy at UBS

Rong Li

Jefferies

$40

Buy

37.17%

Upside

Reiterated

07/14/26

Enovis (ENOV) Receives a Buy from Jefferies

Jeff Johnson

Robert W. Baird

$45→$37

Buy

26.89%

Upside

Reiterated

05/08/26

Enovis price target lowered to $37 from $45 at BairdEnovis price target lowered to $37 from $45 at Baird

Keith Hinton

Freedom Capital Markets

$45

Buy

54.32%

Upside

Initiated

12/16/25

Enovis (ENOV) Initiated with a Buy at Freedom Capital Markets

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

PTGXProtagonist Therapeutics

AXGNAxoGen

ATECAlphatec Holdings

CABACabaletta Bio

ONCBeOne Medicines

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Enovis

3 Months

Jeff JohnsonRobert W. Baird

Success Rate

6/15 ratings generated profit

Average Return

-2.19%

Copying Jeff Johnson's trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of -2.19% per trade.

1 Year

Vijay KumarEvercore ISI

Success Rate

2/14 ratings generated profit

Average Return

-20.89%

Copying Vijay Kumar's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -20.89% per trade.

2 Years

Vijay KumarEvercore ISI

Success Rate

0/14 ratings generated profit

Average Return

-34.55%

Copying Vijay Kumar's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -34.55% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0I1B Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0I1B has received 19 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 0I1B average Analyst price target in the past 3 months is 39.10.

Each month's total comprises the sum of three months' worth of ratings.

0I1B Financial Forecast

0I1B Earnings Forecast

Next quarter’s earnings estimate for 0I1B is $0.77 with a range of $0.74 to $0.83. The previous quarter’s EPS was $0.90. 0I1B beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0I1B has Performed in-line its overall industry.

0I1B Sales Forecast

Next quarter’s sales forecast for 0I1B is $557.46M with a range of $552.27M to $563.00M. The previous quarter’s sales results were $582.78M. 0I1B beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0I1B has Performed in-line its overall industry.

0I1B Stock Forecast FAQ

What is GB:0I1B’s average 12-month price target, according to analysts?

Based on analyst ratings, Enovis’s 12-month average price target is 39.10.

What is GB:0I1B’s upside potential, based on the analysts’ average price target?

Enovis has 34.09% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Enovis a Buy, Sell or Hold?

Enovis has a consensus rating of Strong Buy, which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.

What is Enovis’s share price target?

The average share price target for Enovis is 39.10. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $52.00 ,and the lowest forecast is $27.00. The average share price target represents 34.09% Increase from the current price of $29.16.

What do analysts say about Enovis?

Enovis’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of Enovis?

To buy shares of GB:0I1B, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Enovis (0I1B) Share Forecast & Price Target

0I1B Analyst Ratings

0I1B Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Enovis

0I1B Analyst Recommendation Trends

0I1B Financial Forecast

0I1B Earnings Forecast

0I1B Sales Forecast

0I1B Stock Forecast FAQ

Detailed List of Analyst Forecasts